These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 22188598)

  • 1. Human blood basophils do not act as antigen-presenting cells for the major birch pollen allergen Bet v 1.
    Kitzmüller C; Nagl B; Deifl S; Walterskirchen C; Jahn-Schmid B; Zlabinger GJ; Bohle B
    Allergy; 2012 May; 67(5):593-600. PubMed ID: 22188598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
    Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
    J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation.
    Kitzmüller C; Wallner M; Deifl S; Mutschlechner S; Walterskirchen C; Zlabinger GJ; Ferreira F; Bohle B
    Allergy; 2012 Nov; 67(11):1375-82. PubMed ID: 22973879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
    Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
    Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
    Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
    Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
    J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals.
    Smole U; Radauer C; Lengger N; Svoboda M; Rigby N; Bublin M; Gaier S; Hoffmann-Sommergruber K; Jensen-Jarolim E; Mechtcheriakova D; Breiteneder H
    PLoS One; 2015; 10(1):e0117904. PubMed ID: 25635684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4(+) T cell responses.
    Wambre E; Bonvalet M; Bodo VB; Maillère B; Leclert G; Moussu H; Von Hofe E; Louise A; Balazuc AM; Ebo D; Hoarau C; Garcia G; Van Overtvelt L; Moingeon P
    Clin Exp Allergy; 2011 Feb; 41(2):192-203. PubMed ID: 21105918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel role for neutrophils in IgE-mediated allergy: Evidence for antigen presentation in late-phase reactions.
    Polak D; Hafner C; Briza P; Kitzmüller C; Elbe-Bürger A; Samadi N; Gschwandtner M; Pfützner W; Zlabinger GJ; Jahn-Schmid B; Bohle B
    J Allergy Clin Immunol; 2019 Mar; 143(3):1143-1152.e4. PubMed ID: 29920351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level.
    Bohle B; Radakovics A; Jahn-Schmid B; Hoffmann-Sommergruber K; Fischer GF; Ebner C
    Eur J Immunol; 2003 Dec; 33(12):3303-10. PubMed ID: 14635038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
    Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1-related food allergens.
    Jahn-Schmid B; Radakovics A; Lüttkopf D; Scheurer S; Vieths S; Ebner C; Bohle B
    J Allergy Clin Immunol; 2005 Jul; 116(1):213-9. PubMed ID: 15990797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides.
    Ebner C; Szépfalusi Z; Ferreira F; Jilek A; Valenta R; Parronchi P; Maggi E; Romagnani S; Scheiner O; Kraft D
    J Immunol; 1993 Feb; 150(3):1047-54. PubMed ID: 7678615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
    Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
    Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular composition and biological activity of commercial birch pollen allergen extracts.
    Focke M; Marth K; Valenta R
    Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal digestion of Bet v 1-homologous food allergens destroys their mediator-releasing, but not T cell-activating, capacity.
    Schimek EM; Zwölfer B; Briza P; Jahn-Schmid B; Vogel L; Vieths S; Ebner C; Bohle B
    J Allergy Clin Immunol; 2005 Dec; 116(6):1327-33. PubMed ID: 16337467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoblotting in the diagnosis of cross-reactivity in children allergic to birch.
    Cudowska B; Kaczmarski M; Restani P
    Rocz Akad Med Bialymst; 2005; 50():268-73. PubMed ID: 16358981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.